Infliximab Rescue Therapy in Pediatric Severe Colitis

Area of Science:

• Pediatric Gastroenterology
• Inflammatory Bowel Disease Research
• Clinical Pharmacology

Background:

• Infliximab is used for ulcerative colitis (UC) remission, but its rescue therapy effectiveness in acute severe colitis is debated.
• Pediatric inflammatory bowel disease (IBD) often presents more severely, potentially impacting rescue therapy success.
• This study evaluates inpatient rescue infliximab outcomes in pediatric severe colitis.

Purpose of the Study:

• To assess the effectiveness of inpatient rescue infliximab therapy in pediatric patients with severe ulcerative colitis or indeterminate colitis.
• To identify factors associated with successful infliximab rescue versus colectomy in this population.

Main Methods:

• Retrospective review of pediatric patients (UC or indeterminate colitis) receiving inpatient rescue infliximab (2000-2019).
• Rescue therapy was initiated for non-biologic therapy failure or fulminant/toxic colitis.
• Primary outcome: colectomy following rescue therapy. Statistical significance set at p<0.05.

Main Results:

• 30 patients met criteria; median age 14 years.
• Infliximab rescue therapy succeeded in 33% (10/30), while 67% (20/30) required colectomy.
• Children on maintenance steroids had lower success rates (p=0.03). Colectomy patients had longer hospital stays and antibiotic durations.

Conclusions:

• Infliximab rescue therapy for severe acute ulcerative or indeterminate colitis has a high failure rate, despite potential to avoid colectomy.
• Previous infliximab use was not specified, but outcomes suggest limited efficacy in this severe pediatric cohort.
• Further research into optimal rescue strategies for pediatric severe colitis is warranted.